ZA200606153B - Intranasal administration of glucose-regulating peptides - Google Patents
Intranasal administration of glucose-regulating peptidesInfo
- Publication number
- ZA200606153B ZA200606153B ZA200606153A ZA200606153A ZA200606153B ZA 200606153 B ZA200606153 B ZA 200606153B ZA 200606153 A ZA200606153 A ZA 200606153A ZA 200606153 A ZA200606153 A ZA 200606153A ZA 200606153 B ZA200606153 B ZA 200606153B
- Authority
- ZA
- South Africa
- Prior art keywords
- glucose
- intranasal administration
- regulating peptides
- amylin
- mucosal delivery
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 abstract 2
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 abstract 2
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 abstract 2
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 abstract 2
- 102100040918 Pro-glucagon Human genes 0.000 abstract 2
- 108010011459 Exenatide Proteins 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229960001519 exenatide Drugs 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 108010029667 pramlintide Proteins 0.000 abstract 1
- 229960003611 pramlintide Drugs 0.000 abstract 1
- NRKVKVQDUCJPIZ-MKAGXXMWSA-N pramlintide acetate Chemical compound C([C@@H](C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCCCN)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 NRKVKVQDUCJPIZ-MKAGXXMWSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Otolaryngology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Physiology (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
Pharmaceutical compositions and methods are described comprising at least one glucose-regulating peptide, such as amylin, glucagon-like peptide-1 (GLP), pramlintide or exendin-4 and one or more mucosal delivery-enhancing agents for enhanced nasal mucosal delivery of the amylin, for treating a variety of diseases and conditions in mammalian subjects, including obesity and diabetes mellitus.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53233703P | 2003-12-26 | 2003-12-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200606153B true ZA200606153B (en) | 2007-12-27 |
Family
ID=34748791
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200606153A ZA200606153B (en) | 2003-12-26 | 2006-07-25 | Intranasal administration of glucose-regulating peptides |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20050143303A1 (en) |
| EP (1) | EP1696960B1 (en) |
| JP (1) | JP2007518722A (en) |
| KR (1) | KR20060134036A (en) |
| CN (1) | CN1933855A (en) |
| AT (1) | ATE480259T1 (en) |
| AU (1) | AU2004312043B2 (en) |
| CA (1) | CA2551530A1 (en) |
| DE (1) | DE602004029086D1 (en) |
| ES (1) | ES2350487T3 (en) |
| IL (1) | IL176541A0 (en) |
| MX (1) | MXPA06007317A (en) |
| NO (1) | NO20063436L (en) |
| NZ (1) | NZ548695A (en) |
| WO (1) | WO2005065714A1 (en) |
| ZA (1) | ZA200606153B (en) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070032410A1 (en) * | 2000-01-11 | 2007-02-08 | Atossa Healthcare, Inc. | Compositions and methods for the treatment of psychiatric disorders |
| CA2451839C (en) * | 2001-06-22 | 2013-08-06 | Bentley Pharmaceuticals, Inc. | Pharmaceutical compositions comprising peptides and permeation enhancers |
| US7244703B2 (en) * | 2001-06-22 | 2007-07-17 | Bentley Pharmaceuticals, Inc. | Pharmaceutical compositions and methods for peptide treatment |
| US20050260259A1 (en) * | 2004-04-23 | 2005-11-24 | Bolotin Elijah M | Compositions for treatment with glucagon-like peptide, and methods of making and using the same |
| US7635463B2 (en) * | 2002-02-27 | 2009-12-22 | Pharmain Corporation | Compositions for delivery of therapeutics and other materials |
| US7138105B2 (en) * | 2002-02-27 | 2006-11-21 | Pharmain | Compositions for delivery of therapeutics and other materials, and methods of making and using the same |
| WO2005000222A2 (en) * | 2003-05-30 | 2005-01-06 | Amylin Pharmaceuticals, Inc. | Novel methods and compositions for enhanced transmucosal delivery of peptides and proteins |
| US20080318837A1 (en) * | 2003-12-26 | 2008-12-25 | Nastech Pharmaceutical Company Inc. | Pharmaceutical Formation For Increased Epithelial Permeability of Glucose-Regulating Peptide |
| US20060074025A1 (en) * | 2003-12-26 | 2006-04-06 | Nastech Pharmaceutical Company Inc. | Therapeutic formulations for transmucosal administration that increase glucagon-like peptide-1 bioavailability |
| US20060210614A1 (en) * | 2003-12-26 | 2006-09-21 | Nastech Pharmaceutical Company Inc. | Method of treatment of a metabolic disease using intranasal administration of exendin peptide |
| WO2007065156A2 (en) * | 2005-12-02 | 2007-06-07 | Nastech Pharmaceutical Company Inc. | Pharmaceutical formulation for increased epithelial permeability of glucose-regulating peptide |
| US20090069226A1 (en) * | 2004-05-28 | 2009-03-12 | Amylin Pharmaceuticals, Inc. | Transmucosal delivery of peptides and proteins |
| US8062652B2 (en) | 2004-06-17 | 2011-11-22 | Endo Pharmaceuticals Solutions Inc. | Compositions and methods for treating precocious puberty |
| EP2286840A3 (en) * | 2004-11-01 | 2013-09-04 | Amylin Pharmaceuticals, LLC | Treatment of obesity and related diseases |
| US8394765B2 (en) * | 2004-11-01 | 2013-03-12 | Amylin Pharmaceuticals Llc | Methods of treating obesity with two different anti-obesity agents |
| US7759312B2 (en) * | 2005-03-11 | 2010-07-20 | Endo Pharmaceuticals Solutions Inc. | Delivery of dry formulations of octreotide |
| EP1888043A4 (en) * | 2005-03-11 | 2010-07-28 | Endo Pharmaceuticals Solutions | Controlled release formulations of octreotide |
| ES2670856T3 (en) * | 2005-09-06 | 2018-06-01 | Oramed Pharmaceuticals Inc. | Methods and compositions for oral protein administration |
| US7855279B2 (en) | 2005-09-27 | 2010-12-21 | Amunix Operating, Inc. | Unstructured recombinant polymers and uses thereof |
| WO2007061434A2 (en) * | 2005-11-10 | 2007-05-31 | Nastech Pharmaceutical Company Inc. | A pharmaceutical formulation of glp-1 and its use for treating a metabolic syndrome |
| US20080318861A1 (en) * | 2005-12-08 | 2008-12-25 | Nastech Pharmaceutical Company Inc. | Mucosal Delivery of Stabilized Formulations of Exendin |
| EP1968644B1 (en) | 2005-12-16 | 2012-06-27 | Nektar Therapeutics | Polymer conjugates of glp-1 |
| US20070141145A1 (en) | 2005-12-19 | 2007-06-21 | Pharmaln Ltd. | Hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same |
| US20090318502A1 (en) * | 2006-03-22 | 2009-12-24 | Intranasal Therapeutics, Inc. | Pharmaceutical Compositions Comprising a Hypoglycemic Agent and Methods of Using Same |
| WO2007146448A1 (en) * | 2006-06-07 | 2007-12-21 | Nastech Pharmaceutical Company Inc. | Pharmaceutical formulations of glp-1 derivatives |
| JP2010043001A (en) * | 2006-11-09 | 2010-02-25 | Sanwa Kagaku Kenkyusho Co Ltd | Glp-1 derivative and use thereof |
| US9120249B2 (en) * | 2007-04-27 | 2015-09-01 | Endo Pharmaceuticals Solutions Inc. | Implant device release agents and methods of using same |
| US7960336B2 (en) * | 2007-08-03 | 2011-06-14 | Pharmain Corporation | Composition for long-acting peptide analogs |
| US8563527B2 (en) * | 2007-08-20 | 2013-10-22 | Pharmain Corporation | Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same |
| JP5385279B2 (en) * | 2007-09-11 | 2014-01-08 | モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト | Use of gonadorelin as a therapeutic agent |
| US20090176892A1 (en) | 2008-01-09 | 2009-07-09 | Pharmain Corporation | Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same |
| RU2504373C2 (en) | 2008-03-26 | 2014-01-20 | ОРАМЕД Лтд. | Methods and compositions for oral administration of proteins |
| CN101548961B (en) * | 2008-04-03 | 2011-05-04 | 单宝华 | Novel oral capsule preparation for curing diabetes mellitus and obesity |
| EP2300031B1 (en) * | 2008-05-05 | 2017-09-20 | Oramed Ltd. | Methods and compositions for oral administration of exenatide |
| JP5536053B2 (en) | 2008-06-25 | 2014-07-02 | エンド ファーマスーティカルズ ソリューションズ インコーポレイテッド． | Octreotide implant with release agent |
| EP2303226B1 (en) * | 2008-06-25 | 2016-03-23 | Endo Pharmaceuticals Solutions Inc. | Sustained delivery of exenatide and other polypeptides |
| LT2393828T (en) | 2009-02-03 | 2017-01-25 | Amunix Operating Inc. | Extended recombinant polypeptides and compositions comprising same |
| US20100203014A1 (en) * | 2009-02-04 | 2010-08-12 | Aegis Therapeutics Llc | Zwitterionic buffered acidic peptide and protein formulations |
| CN101822822A (en) * | 2009-03-04 | 2010-09-08 | 北京德众万全药物技术开发有限公司 | Drug composition of pramlintide and preparation method thereof |
| JP5839597B2 (en) * | 2009-06-08 | 2016-01-06 | アムニクス オペレーティング インコーポレイテッド | Glucose-regulating polypeptide and methods for making and using the same |
| CN102309453A (en) * | 2011-09-27 | 2012-01-11 | 四川大学 | Exenatide multivesicular liposome and preparation method thereof |
| US10398762B2 (en) | 2012-01-03 | 2019-09-03 | Oramed Ltd. | Methods and compositions for treating diabetes |
| EP4082530B1 (en) | 2012-02-01 | 2024-04-10 | Oramed Ltd. | Protease inhibitor-containing compositions, compositions comprising same, and methods for producing and using same |
| UA116217C2 (en) | 2012-10-09 | 2018-02-26 | Санофі | Exendin-4 derivatives as dual glp1/glucagon agonists |
| PE20151239A1 (en) | 2012-12-21 | 2015-09-08 | Sanofi Sa | DERIVATIVES OF EXENDIN-4 FUNCTIONALIZED |
| CN110151979A (en) | 2013-01-03 | 2019-08-23 | 奥拉姆德有限公司 | For treating NAFLD, hepatic steatosis and its method and composition of sequelae |
| BR102013017626A2 (en) * | 2013-06-14 | 2015-02-10 | Univ Rio De Janeiro | NON-AGGLOMANTANT BIOCONJUGATES WITH POLYETHYLENEGLYCOL, NON-AGGLOMANTANT BIOCONJUGATES WITH POLYETHYLENEGLYCOL, PHARMACEUTICAL COMPOSITIONS OF LOW TOXICITY, ADJUSTING OR PREVENTION OF THE PREVENTION OF PREVENTION MEASUREMENT |
| CN103405753B (en) * | 2013-08-13 | 2016-05-11 | 上海仁会生物制药股份有限公司 | Stable insulin secretion accelerating peptide liquid drugs injection pharmaceutical composition |
| TW201609795A (en) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | EXENDIN-4 peptide analogues as dual GLP-1/GIP receptor agonists |
| TW201609796A (en) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | Non-acylated EXENDIN-4 peptide analogues |
| WO2015086733A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/glucagon receptor agonists |
| EP3080154B1 (en) | 2013-12-13 | 2018-02-07 | Sanofi | Dual glp-1/gip receptor agonists |
| TW201625669A (en) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | Peptidic dual GLP-1/glucagon receptor agonists derived from Exendin-4 |
| TW201625668A (en) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists |
| TW201625670A (en) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | Dual GLP-1/glucagon receptor agonists derived from EXENDIN-4 |
| CN103948544B (en) * | 2014-04-08 | 2016-02-17 | 河南农业大学 | Restructuring Exendin-4 nasal mist and preparation method thereof |
| US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
| AR105319A1 (en) | 2015-06-05 | 2017-09-27 | Sanofi Sa | PROPHARMS THAT INCLUDE A DUAL AGONIST GLU-1 / GLUCAGON CONJUGATE HIALURONIC ACID CONNECTOR |
| AR105284A1 (en) | 2015-07-10 | 2017-09-20 | Sanofi Sa | DERIVATIVES OF EXENDINA-4 AS SPECIFIC DUAL PEPTIDE AGONISTS OF GLP-1 / GLUCAGÓN RECEPTORS |
| EP3117831A1 (en) * | 2015-07-16 | 2017-01-18 | Nuritas Limited | Peptides for use in promoting transport of glucose into skeletal muscle |
| ES2976496T3 (en) | 2017-08-24 | 2024-08-02 | Novo Nordisk As | GLP-1 compositions and uses thereof |
| CN108079280B (en) * | 2017-12-30 | 2021-06-04 | 陕西慧康生物科技有限责任公司 | Exenatide nasal drops for treating type II diabetes |
| CN109136176A (en) * | 2018-07-03 | 2019-01-04 | 华东师范大学 | A kind of mouse cryopreservation sperm resuscitation fluid compound and its preparation method and application |
| US20230082544A1 (en) | 2020-02-18 | 2023-03-16 | Novo Nordisk A/S | Pharmaceutical formulations |
| CN117979954A (en) * | 2021-09-22 | 2024-05-03 | 辉凌有限公司 | Corticotropin peptide compositions and methods of use |
| CN118001259B (en) * | 2024-02-06 | 2024-09-20 | 上海万良诚科医药科技有限公司 | Triptorelin buccal membrane and preparation method thereof |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US3972995A (en) * | 1975-04-14 | 1976-08-03 | American Home Products Corporation | Dosage form |
| US4235871A (en) * | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| JPS5562012A (en) * | 1978-11-06 | 1980-05-10 | Teijin Ltd | Slow-releasing preparation |
| GB2042888B (en) * | 1979-03-05 | 1983-09-28 | Teijin Ltd | Preparation for administration to the mucosa of the oral or nasal cavity |
| US4259314A (en) * | 1979-12-10 | 1981-03-31 | Hans Lowey | Method and composition for the preparation of controlled long-acting pharmaceuticals |
| US4675189A (en) * | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
| JPS57110254A (en) * | 1980-12-29 | 1982-07-09 | Teijin Ltd | Coating agent of injured membrane part of oral cavity |
| ATE21633T1 (en) * | 1981-06-04 | 1986-09-15 | Pharmasol Corp | PRESSURE TANK WITH DISPENSING PUMP. |
| US4501728A (en) * | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| JPS60100516A (en) * | 1983-11-04 | 1985-06-04 | Takeda Chem Ind Ltd | Preparation of sustained release microcapsule |
| US4680323A (en) * | 1983-12-01 | 1987-07-14 | Hans Lowey | Method and composition for the preparation of controlled long-acting pharmaceuticals for oral administration |
| US4573996A (en) * | 1984-01-03 | 1986-03-04 | Jonergin, Inc. | Device for the administration of an active agent to the skin or mucosa |
| DE3580384D1 (en) * | 1984-04-09 | 1990-12-13 | Toyo Boseki | PREPARATION WITH DELAYED RELEASE FOR APPLICATION ON THE ORIGINAL SLIME. |
| CA1256638A (en) * | 1984-07-06 | 1989-06-27 | Motoaki Tanaka | Polymer and its production |
| JP2551756B2 (en) * | 1985-05-07 | 1996-11-06 | 武田薬品工業株式会社 | Polyoxycarboxylic acid ester and method for producing the same |
| JPH0729915B2 (en) * | 1986-02-01 | 1995-04-05 | 帝國製薬株式会社 | Sheet-shaped oral patch |
| CA1341320C (en) | 1986-05-05 | 2001-11-20 | Joel Habener | Insulinotropic hormone |
| USRE33093E (en) * | 1986-06-16 | 1989-10-17 | Johnson & Johnson Consumer Products, Inc. | Bioadhesive extruded film for intra-oral drug delivery and process |
| US4837028A (en) * | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US4855142A (en) * | 1987-02-27 | 1989-08-08 | Ciba-Geigy Corporation | Pharmaceutical plaster |
| EP0308181A1 (en) * | 1987-09-14 | 1989-03-22 | Novo Nordisk A/S | Trans-mucosal delivery formulations and a method for preparation thereof |
| US4948580A (en) * | 1988-12-08 | 1990-08-14 | E. R. Squibb & Sons, Inc. | Muco-bioadhesive composition |
| NL9001681A (en) * | 1990-07-24 | 1992-02-17 | Rijksuniversiteit | TRANSMUCOSAL MEDICINAL PRODUCT PREPARATIONS AND TRANSMUCOSAL ADMINISTRATION. |
| DK36492D0 (en) * | 1992-03-19 | 1992-03-19 | Novo Nordisk As | PREPARATION |
| US6190894B1 (en) * | 1993-03-19 | 2001-02-20 | The Regents Of The University Of California | Method and compositions for disrupting the epithelial barrier function |
| US5681811A (en) * | 1993-05-10 | 1997-10-28 | Protein Delivery, Inc. | Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same |
| US5424286A (en) | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
| JPH0859503A (en) * | 1994-08-26 | 1996-03-05 | Teijin Ltd | Liposome preparation for administering pepide or protein medicine through mouth or mucosa |
| US6004583A (en) * | 1995-03-22 | 1999-12-21 | Orex Pharmaceutical Development Corp. | Protein-containing polymer composition for oral administration |
| JPH11292787A (en) * | 1995-08-15 | 1999-10-26 | Asahi Chem Ind Co Ltd | Transucosal preparation containing physiologically active peptide |
| ATE316100T1 (en) * | 1996-06-05 | 2006-02-15 | Roche Diagnostics Gmbh | EXENDIN ANALOGAS, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING SAME |
| US7312196B2 (en) * | 1997-01-08 | 2007-12-25 | Amylin Pharmaceuticals, Inc. | Formulations for amylin agonist peptides |
| US5908825A (en) * | 1997-01-09 | 1999-06-01 | University Of Maryland At Baltimore | Dosage composition for nasal delivery and method of use of the same |
| US6221378B1 (en) * | 1998-02-10 | 2001-04-24 | Generex Pharmaceuticals Incorporated | Mixed micellar delivery system and method of preparation |
| US20030087820A1 (en) * | 1999-01-14 | 2003-05-08 | Young Andrew A. | Novel exendin agonist formulations and methods of administration thereof |
| US6506724B1 (en) * | 1999-06-01 | 2003-01-14 | Amylin Pharmaceuticals, Inc. | Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus |
| US6528486B1 (en) * | 1999-07-12 | 2003-03-04 | Zealand Pharma A/S | Peptide agonists of GLP-1 activity |
| US20010012829A1 (en) * | 2000-01-11 | 2001-08-09 | Keith Anderson | Transepithelial delivery GLP-1 derivatives |
| US6540983B1 (en) * | 2000-01-25 | 2003-04-01 | Aeropharm Technology Incorporated | Medical aerosol formulation |
| US20050222036A1 (en) * | 2000-08-24 | 2005-10-06 | Thomas Jefferson University | Peptide compositions with effects on blood glucose |
| ES2298378T3 (en) * | 2001-06-28 | 2008-05-16 | Novo Nordisk A/S | STABLE FORMULATION OF MODIFIED GLP-1. |
| DE60332856D1 (en) * | 2002-10-23 | 2010-07-15 | Bristol Myers Squibb Co | GLYCINNITRIL BASED DIPEPTIDYLPEPTIDASE IV INHIBITORS |
| US20040258663A1 (en) * | 2003-05-08 | 2004-12-23 | Nastech Pharmaceutical Company Inc. | Compositions and methods for enhanced mucosal delivery of interferon alpha |
| WO2005000222A2 (en) * | 2003-05-30 | 2005-01-06 | Amylin Pharmaceuticals, Inc. | Novel methods and compositions for enhanced transmucosal delivery of peptides and proteins |
| US20060210614A1 (en) * | 2003-12-26 | 2006-09-21 | Nastech Pharmaceutical Company Inc. | Method of treatment of a metabolic disease using intranasal administration of exendin peptide |
-
2004
- 2004-11-18 US US10/991,597 patent/US20050143303A1/en not_active Abandoned
- 2004-12-17 JP JP2006547366A patent/JP2007518722A/en active Pending
- 2004-12-17 DE DE602004029086T patent/DE602004029086D1/en not_active Expired - Lifetime
- 2004-12-17 EP EP04815393A patent/EP1696960B1/en not_active Expired - Lifetime
- 2004-12-17 AT AT04815393T patent/ATE480259T1/en not_active IP Right Cessation
- 2004-12-17 WO PCT/US2004/043312 patent/WO2005065714A1/en active Application Filing
- 2004-12-17 ES ES04815393T patent/ES2350487T3/en not_active Expired - Lifetime
- 2004-12-17 CA CA002551530A patent/CA2551530A1/en not_active Abandoned
- 2004-12-17 NZ NZ548695A patent/NZ548695A/en unknown
- 2004-12-17 AU AU2004312043A patent/AU2004312043B2/en not_active Ceased
- 2004-12-17 CN CNA2004800421626A patent/CN1933855A/en active Pending
- 2004-12-17 MX MXPA06007317A patent/MXPA06007317A/en active IP Right Grant
- 2004-12-17 KR KR1020067015029A patent/KR20060134036A/en not_active Ceased
-
2006
- 2006-06-25 IL IL176541A patent/IL176541A0/en unknown
- 2006-07-25 NO NO20063436A patent/NO20063436L/en not_active Application Discontinuation
- 2006-07-25 ZA ZA200606153A patent/ZA200606153B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20050143303A1 (en) | 2005-06-30 |
| NO20063436L (en) | 2006-08-25 |
| JP2007518722A (en) | 2007-07-12 |
| AU2004312043A1 (en) | 2005-07-21 |
| MXPA06007317A (en) | 2007-01-26 |
| ATE480259T1 (en) | 2010-09-15 |
| ES2350487T3 (en) | 2011-01-24 |
| CN1933855A (en) | 2007-03-21 |
| NZ548695A (en) | 2008-04-30 |
| WO2005065714A1 (en) | 2005-07-21 |
| CA2551530A1 (en) | 2005-07-21 |
| DE602004029086D1 (en) | 2010-10-21 |
| EP1696960B1 (en) | 2010-09-08 |
| IL176541A0 (en) | 2006-10-05 |
| EP1696960A1 (en) | 2006-09-06 |
| AU2004312043B2 (en) | 2008-07-31 |
| KR20060134036A (en) | 2006-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200606153B (en) | Intranasal administration of glucose-regulating peptides | |
| AR022368A1 (en) | PROCEDURE FOR MANAGING INSULINOTROPIC PEPTIDES | |
| ATE251642T1 (en) | BIOLOGICALLY ACTIVE FRAGMENTS OF GLUCAGON-LIKE INSULINOTROPIC PEPTIDES | |
| WO2006121860A3 (en) | Glucagon-like peptide 1 (glp-1) receptor agonists and their pharmacological methods of use | |
| EP3080150B1 (en) | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists | |
| WO2003011892A3 (en) | Glp-1 exendin-4 peptide analogs and uses thereof | |
| WO2005115441A3 (en) | Compositions and methods for enhanced mucosal delivery of parathyroid hormone | |
| DK1171465T3 (en) | Analogues to gastroinhibitory peptide and their use in the treatment of diabetes | |
| PL2301962T3 (en) | Invention affecting GLP-1 and Exendin | |
| JP2004509079A5 (en) | ||
| WO2003033671A3 (en) | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions | |
| WO1999043705A8 (en) | N-terminally truncated glp-1 derivatives | |
| DE69942307D1 (en) | N-TERMINAL CHANGED GLP-1 ABÖMMLINGE | |
| NZ621196A (en) | Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage | |
| WO2004056314A3 (en) | Compositions and methods for enhanced mucosal delivery of y2 receptor-binding peptides and methods for treating and preventing obesity | |
| WO2008076933A3 (en) | Long acting proteins and peptides and methods of making and using the same | |
| NO20082958L (en) | Human glucagon-like peptide-1 modulators and their use in the treatment of diabetes and related conditions | |
| WO2004094461A3 (en) | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions | |
| MX2022009149A (en) | Gip/glp1 co-agonist compounds. | |
| IL146868A0 (en) | A pharmaceutical composition containing an igf-i/igfbp-3 complex | |
| Youn et al. | Improved peroral delivery of glucagon-like peptide-1 by site-specific biotin modification: design, preparation, and biological evaluation | |
| ZA202301635B (en) | Ham15-52 analogues with improved amylin receptor (hamy3r) potency | |
| WO2005004899A3 (en) | Biologically active substance of a vasoactive intestinal peptide for treating interstitial lung infections | |
| WO2006121588A3 (en) | Pituitary adenylate cyclase activating peptide (pacap) receptor (vpac2) agonists and their pharmacological methods of use | |
| WO2005117584A3 (en) | Improved transmucosal delivery of peptides and proteins |